Skip to content

Screening and validation of biomarkers for early esophageal cancer detection.

Screening and validation of biomarkers for early esophageal cancer detection.

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107296
Enrollment
Unknown
Registered
2025-08-07
Start date
2025-08-15
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophagus cancer

Interventions

Gold Standard:Endoscopic findings or histopathologic testing results are the gold standard for esophageal cancer or benign diseases of the gastrointestinal tract.
Index test:miRNAs and microorganisms in oral saliva

Sponsors

The First Affiliated Hospital of Xiamen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. >= 18 years old. 2. The subjects have undergone or plan to undergo esophageal endoscopy and can obtain the endoscopy results or histopathological test results. 3. Agree to participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Breastfeeding or pregnant women; 2. Individuals with a history of esophageal cancer; 3. Those who have previously received therapeutic interventions for esophageal cancer, such as surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.; 4. Patients with other primary malignant tumors within the past 5 years (patients who have been diagnosed with other cancers, treated and stable for over 5 years may be included); 5. Individuals with severe cardiac, pulmonary, hepatic, renal insufficiency or other serious systemic diseases; 6. Patients with infectious diseases, such as hepatitis B, hepatitis C, HIV infection, etc.; 7. Those with mental disorders or psychological diseases that make it impossible to comply with study requirements; 8. Individuals who cannot meet the study's testing requirements due to sampling issues; 9. Other individuals deemed unsuitable for participation in this clinical trial by the investigator.

Design outcomes

Primary

MeasureTime frame
AUC;sensitivity;specificity;

Countries

China

Contacts

Public ContactJiang Jie

The First Affiliated Hospital of Xiamen University

ygz23230286@163.com+86 138 0603 2186

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026